APTO
- Aptose Biosciences Inc.
()
Overview
Company Summary
Aptose Biosciences Inc. (APTO) is a biopharmaceutical company that focuses on developing and commercializing targeted therapies to treat life-threatening cancers. The company's primary goal is to provide novel and effective treatment options for patients who have limited or no existing treatments available.
Aptose Biosciences utilizes a unique approach known as rational drug design to create new small molecule therapeutics. This approach involves the identification and understanding of specific biological targets that play a crucial role in the development and progression of cancer. By targeting these specific molecular pathways, Aptose aims to develop drugs that can inhibit or modulate their function, ultimately impeding the growth and survival of cancer cells.
The company's drug development pipeline primarily focuses on a class of mutations called oncogenic driver mutations. These mutations are responsible for driving the growth of cancer cells and are found in a variety of cancer indications, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Aptose's lead drug candidate, APTO-253, is currently being investigated for the treatment of AML and MDS.
In addition to its lead drug candidate, Aptose Biosciences continues to advance other early-stage preclinical programs. These programs encompass a range of molecular targets and therapeutic approaches, including kinase inhibitors and epigenetic modulators.
Overall, Aptose Biosciences Inc. is dedicated to advancing innovative therapies that have the potential to make a significant impact in the treatment of life-threatening cancers. Through its focus on rational drug design and targeted drug development, Aptose aims to improve patient outcomes and address unmet medical needs in the field of oncology.